Proteasome inhibitors: an expanding army attacking a unique target

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Proteasomes are large, multi-subunit proteolytic complexes crucial for cellular regulation.
• The 26S proteasome comprises a 20S proteolytic core and 19S regulatory particles, each offering therapeutic targets.
• Diverse proteasome inhibitors have been identified, with bortezomib currently in clinical use.

Purpose of the Study:

• To review the therapeutic potential of proteasome inhibitors.
• To highlight the development of novel proteasome inhibitors for various diseases.
• To explore emerging targets within the 19S regulatory particle.

Main Methods:

• Literature review of natural product and synthetic proteasome inhibitors.
• Analysis of clinical trial data for approved and investigational proteasome inhibitors.
• Examination of preclinical data for proteasome inhibitors in various disease models.

Main Results:

• Bortezomib is clinically approved for multiple myeloma, mantle cell lymphoma, and acute allograft rejection.
• Several novel proteasome inhibitors are in clinical trials for myeloma and other cancers.
• Proteasome inhibitors demonstrate efficacy in preclinical models of autoimmune diseases, inflammatory conditions, and reperfusion injury.

Conclusions:

• Proteasome inhibitors represent a significant class of therapeutics with broad clinical applications.
• Ongoing research is expanding the therapeutic landscape of proteasome inhibition beyond cancer.
• Targeting ATPases and deubiquitinases of the 19S regulatory particle presents a promising avenue for future drug development.